Trial Profile
A randomized comparison of the effect of empagliflozin for endothelial function in type 2 diabetes
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 18 Mar 2022
Price :
$35
*
At a glance
- Drugs Empagliflozin (Primary) ; Insulin glargine (Primary) ; Metformin (Primary) ; Glimepiride
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- 26 Jun 2018 Status changed from recruiting to completed, according to the results presented at the 78th Annual Scientific Sessions of the American Diabetes Association.
- 26 Jun 2018 Primary endpoint (Change of FMD% with additional treatment before and after 12 weeks) has not been met, according to the results presented at the 78th Annual Scientific Sessions of the American Diabetes Association.
- 26 Jun 2018 Results presented at the 78th Annual Scientific Sessions of the American Diabetes Association.